Genomic characteristics, disease outcome and heterologous vaccine effectiveness among cases with SARS CoV-2 infection.

导出 OA

翻译打印收藏纠错

第一作者： Rowan,Abuyadek

第一单位： Abu Dhabi Department of Health, Abu Dhabi Public Health Center, Abu Dhabi, United Arab Emirates.;High Institute of Public Health, Alexandria University, Alexandria, Egypt.

作者： Rowan,Abuyadek ^[1] ; Mira,Mousa ^[2] ; Jumana,AlAzazi ^[3] ; Ahmed,Al Romaithi ^[4] ; Francis,Selvaraj ^[5] ; Habiba,Alsafar ^[6] ; Nawal,Al Kaabi ^[7] ; Farida,Al Hosani ^[8]

作者单位： Abu Dhabi Department of Health, Abu Dhabi Public Health Center, Abu Dhabi, United Arab Emirates.;High Institute of Public Health, Alexandria University, Alexandria, Egypt. ^[1] Center for Biotechnology, Khalifa University, Abu Dhabi, UAE.;Department of Public Health and Epidemiology, College of Medicine and Health Science, Khalifa University, Abu Dhabi, UAE. ^[2] Abu Dhabi Executive Office, Abu Dhabi, UAE. ^[3] Department SKMC-CEO, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. ^[4] Reference Laboratory for Infectious Disease (RLID), Department Laboratory Medicine Services, Sheikh Khalifa Medical City, PureLab, Abu Dhabi, United Arab Emirates. ^[5] Center for Biotechnology, Khalifa University, Abu Dhabi, UAE.;Department of Biomedical Engineering and Biotechnology, College of Medicine and Health Science, Khalifa University, Abu Dhabi, UAE. ^[6] College of Medicine and Health Science, Khalifa University, Abu Dhabi, UAE. alkaabin971@gmail.com.;Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates. alkaabin971@gmail.com. ^[7] Abu Dhabi Department of Health, Abu Dhabi Public Health Center, Abu Dhabi, United Arab Emirates. ^[8]

关键词 Booster Heterologous Homologous Pandemic SARS CoV-2 Severity Vaccine Variant of concern virus